Development
Bristol-Myers Squibb Company
BMY
$48.44
$0.631.32%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 11.48B | 10.97B | 11.23B | 11.34B | 11.41B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.48B | 10.97B | 11.23B | 11.34B | 11.41B |
| Cost of Revenue | 2.71B | 2.49B | 2.81B | 2.51B | 2.52B |
| Gross Profit | 8.77B | 8.48B | 8.42B | 8.83B | 8.89B |
| SG&A Expenses | 2.06B | 1.94B | 1.91B | 1.76B | 2.26B |
| Depreciation & Amortization | 2.28B | 2.26B | 2.26B | 2.26B | 2.34B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.53B | 8.86B | 9.23B | 8.83B | 9.63B |
| Operating Income | 1.95B | 2.10B | 1.99B | 2.51B | 1.77B |
| Income Before Tax | 1.67B | 2.14B | 1.86B | 2.77B | 1.86B |
| Income Tax Expenses | -88.00M | 203.00M | -218.00M | 503.00M | -166.00M |
| Earnings from Continuing Operations | 1.76B | 1.93B | 2.08B | 2.27B | 2.03B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | -6.00M | -4.00M | -5.00M | -3.00M |
| Net Income | 1.76B | 1.93B | 2.07B | 2.26B | 2.02B |
| EBIT | 1.95B | 2.10B | 1.99B | 2.51B | 1.77B |
| EBITDA | 4.37B | 4.56B | 4.45B | 4.95B | 4.22B |
| EPS Basic | 0.87 | 0.94 | 0.99 | 1.08 | 0.96 |
| Normalized Basic EPS | 0.72 | 0.76 | 0.69 | 0.85 | 0.59 |
| EPS Diluted | 0.87 | 0.93 | 0.99 | 1.07 | 0.95 |
| Normalized Diluted EPS | 0.71 | 0.76 | 0.69 | 0.84 | 0.59 |
| Average Basic Shares Outstanding | 2.03B | 2.06B | 2.09B | 2.10B | 2.11B |
| Average Diluted Shares Outstanding | 2.03B | 2.06B | 2.10B | 2.11B | 2.12B |
| Dividend Per Share | 0.60 | 0.57 | 0.57 | 0.57 | 0.57 |
| Payout Ratio | 65.83% | 61.77% | 57.74% | 52.87% | 56.63% |